MedTrace Logo

Mechanisms of Diabetic Kidney Disease in American Indians

NCT01878045 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 141

Last updated 2026-05-07

No results posted yet for this study

Summary

Background:

\- An ongoing study is looking at American Indians who have kidney problems caused by type 2 diabetes. Kidney disease due to type 2 diabetes is a major problem in American Indians. We previously found that early treatment of kidney disease with losartan was probably beneficial for reducing progression of the disease. Researchers now want to see if these benefits continue to be seen several years after the end of the treatment study.

Objectives:

\- To study long-term benefit of losartan treatment for diabetic kidney disease in American Indians with type 2 diabetes.

Eligibility:

\- Participants in the American Indian diabetic kidney disease study (OH95-DK-N037).

Design:

* Participants will have a physical exam and medical history before starting the study. Blood and urine samples will be collected.
* Participants will have a set of tests as part of this study. Those who have severe kidney problems, such as kidney failure, will only have a basic kidney exam with scans. The remaining participants will have a full urine collection and analysis. They will also provide a kidney biopsy.
* Treatment will not be provided as part of this study.

Conditions

  • Nervous System
  • Diabetic Kidney Disease
  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Helen C Looker · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-07
Primary Completion
2019-07-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01878045 on ClinicalTrials.gov